Results 101 to 110 of about 10,614 (201)
Púrpura Trombocitopénica Idiopática Infantil. Cuidados Integrales
NURE Investigación, 2012 Púrpura trombocitopénica idiopática o PTI es el trastorno hemorrágico autoinmunitario más frecuente en niños/as. A partir del Proceso de Atención de Enfermería, el personal de enfermería desde una perspectiva holística llevará a cabo los cuidados al niño/
Carmen Tamara González Fernández
doaj
Indian Journal of Ophthalmology, 2010 A 42-year-old female presented to us with a complaint of sudden painless loss of vision in both eyes of three days duration. Visual acuity was 20/100 for distance in both eyes.
Majji Ajit, Bhatia Kapil, Mathai Annie
doaj
Caracterización epidemiológica, clínica y laboratorial de los pacientes con púrpura trombocitopénica inmune atendidos en dos hospitales de Lambayeque, 2018-2022 [PDF]
Antecedentes: La Púrpura trombocitopénica Inmune (PTI) tiene una incidencia anual de 6.1 por cada 100 000 personas, puede afectar tanto niños y adultos en su forma aguda y crónica; pueden presentar equimosis, petequias y sangrado en mucosas.
Celis Cortez, Diana Antonella
core
Methodological challenges in post-licensure vaccine safety studies using large routinely collected datasets [PDF]
, 2017 Robust and responsive epidemiological post-licensure vaccine safety studies are the backbone to having confidence in a vaccination programme. Consideration must be given to the unique methodological challenges inherent when assessing a potential causal
Toffa-Stowe, Julia Margaret
core
Long-term use of anti-D in chronic idiopathic thrombocytopenic purpura
The Turkish Journal of Pediatrics, 1994 Chronic idiopathic thrombocytopenic purpura is an autoimmune disease characterized by antibody-mediated destruction of platelets. To maintain the platelets above the symptomatic level, we administered anti-D (100 micrograms for 5 consecutive days)
I Yaprak +5 more
doaj
Stratified medicine: methods for evaluation of predictive biomarkers [PDF]
, 2017 Background: Stratified medicine was defined as the use of biomarkers to select patients more likely to respond to a treatment or experience an adverse event.
Malottki, Kinga
core
VACCINE BENEFIT AND RISK ASSESSMENT FOR AN INFECTIOUS DISEASE WITH PANDEMIC POTENTIAL USING QUALITY-ADJUSTED LIFE YEAR [PDF]
During the COVID-19 pandemic, vaccines, including messenger ribonucleic acid (mRNA) vaccines, were rapidly developed, manufactured, and delivered.
Kitano, Taito
core +3 more sources